QantX
  • Home
  • Invest
  • Team
  • Strategy
  • Portfolio
  • News
  • Contact
  • Investor Portal
Select Page
Portfolio company Neuronostics raise over £2M in oversubscribed seed round

Portfolio company Neuronostics raise over £2M in oversubscribed seed round

by Harry | Apr 5, 2024 | Portfolio

SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease

SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease

by Harry | Mar 27, 2024 | Portfolio

The SETsquared partnership named by FT and Sifted in top 3 startup hubs of Europe

The SETsquared partnership named by FT and Sifted in top 3 startup hubs of Europe

by Harry | Mar 14, 2024 | Uncategorized

Beyond the Golden Triangle

Beyond the Golden Triangle

by Harry | Sep 12, 2023 | Climate, Healthcare, Innovation

Last week, our second annual Investor Showcase Day welcomed nearly 100 founders, investors, advisors, and startup ecosystem pioneers. We were delighted to celebrate the strides our portfolio companies have taken over the past year and to unveil our new fundraising...
Next Entries »

Latest Posts

  • SENISCA: treating age-related diseases with ground-breaking science
  • Lutra Health: integrating community and hospital eyecare
  • QantX leads £600K investment round to speed up innovation in the quantum industry
  • Supporting the Full Innovation Stack: From Lab Discovery to Global Impact
  • QantX partners with the SETsquared Partnership universities on new £300m investment vehicle

enquiries@qantx.co.uk  

Investor Area

QantX (Reference number: 954072) is an Appointed Representative of Kin Capital Partners LLP (FRN: 656789). Kin Capital Partners LLP (trading as Kin Fund Services) is authorised and regulated by the Financial Conduct Authority.

© 2022 QantX. All rights reserved. Cookie Policy | Privacy Policy

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy